透析療法ネクスト　II　透析骨症は防げる

出版社： 医学図書出版
著者：
発行日： 2002-12-27
分野： 臨床医学：内科  >  腎臓
ISBN： 487151319x
電子書籍版： 2002-12-27
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,860 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,430 円(税込)

購入する

商品紹介

本特集号は、「カルシウム・リン代謝異常」に対する治療法の変革期に、患者様に直接接する透析従事者に、日常の診療に役立つ情報を提供できるものとして本号を企画した。本号が読者の新しい治療薬に対する理解を深め、透析患者様のカルシウム・リン代謝異常の改善に役立つものと期待している。

目次

  • 透析療法ネクスト　II　透析骨症は防げる

    ―　目次　―

    ■特集　「透析骨症は防げる」
    透析のstrategyと骨カルシウム代謝治療　　溝渕正英ほか
    骨代謝研究の最近の進歩と透析骨症の理解　　風間順一郎ほか
    リン代謝の最近の理解とリン調節薬の将来　　桑波田雅士ほか
    骨生検からわかること、しなくてもわかること　　栗原怜
    透析骨症における骨塩量測定の役割　　奥野仙二ほか
    血清ビタミンD濃度測定は骨カルシウム代謝治療に必要か　　弓田滋
    透析骨症進展防止のためにビタミンD製剤をどう使い分けるか？　　重松隆ほか
    透析骨症の予防と治療―過去、現在、将来への展望　　木全直樹ほか

    ほか

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

特集 『透析骨症は防げる』

P.25 掲載の参考文献
1) Slatopolsky EA, et al. : Marked supression of secondary hyperparathyroidism by intervenous administration of 125-dihydroxycholecalciferol in uremic patients. J Clin Invest 74 : 2136-2143, 1984.
 
2) Korkor AB : Reduced binding of [3H] 125 dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Endl J Med 316 : 1573-1577, 1987.
 
3) Sawaya BP, Koszewski NJ, Qi Q, et al. : Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal fallure. J Am Soc Nephrol 8 : 271-278, 1997.
 
4) Patel SR, Ke HQ, Vanholder R, et al. : Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest 96 : 50-59, 1995.
PubMed
5) Brown EM : Extracelular calcium sensing and calcium signaUng. Physiol Rev 32 : 240-297, 2001.
 
6) Kifbr O, Moore FDJ, Wang P, et al. : Reduced immunostaining for the extracellular Ca2+ -sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81 : 1598-1606, 1996.
 
7) Ritter CS, Finch JL, Slatopolsky EA, et al. : Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int 60 : 1737-1744, 2001.
PubMed
8) Bourdeau A, Moutahir M, SouberbieUe JC, et al. : Effects of lipoxygenase products of arachidonate metabolism on parathyroid hormone secretion. Endcrinol 135 : 1109-1112, 1994.
 
9) Almaden Y, Canalejo A, Ballesteros E, et al. : Regulation of arachidonic acid production by intraceUular calcium in parathyroid cells : Effect of extraceUular phosphate. J Am Soc Nephrol 13 : 693-698, 2002.
 
10) Slatopolsky EA, Frinch J, Denda M, et al. : Phosphorus restriction prevents parathyroid gland growth ; High phosphorus directly stimulates PTH secretion in vivo. J Clin Invest 97 : 2534-2540, 1996.
 
11) Hayakawa Y, Tanaka Y, Funahashi H, et al. : Hyperphosphatemia accelerates parathyroid cell proliferation and parathyroid hormone secretion in severe secondary parathyroid hyperplasia. Endocr J 46 : 681-686, 1999.
PubMed
12) Moalem E, Kilav R, Silver J, et al. : RNA-protein binding and posttranscriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 273 : 5253-5259, 1998.
 
13) Takahashi F, Denda M, Finch JL, et al. : Hyperplasia of parathyroid gland without secondary hyperparathyroidism. Kidney Int 61 : 1332-1338, 2002.
PubMed
14) Slatopolsky EA, Bruke SK, Dillon MA, et al. : Renagel, a nonabsorbed calciumand alminiumfree phosphate binder, loweres serum phosphorus and parathyroid hormone. Kidney Int 55 : 299-307, 999.
 
15) Collins AJ, Peter WLS, Dalleska FW, et al. : Hospitahzation risks between Renagel phosphate binder treated and non-Renagel treated padents. Clm Nephrol 54 : 334-341, 2000.
 
16) Nagano N, Miyata S, Obana S, et al. : Sevelamer hydrochroride (Renagel), anon-calcemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufiiciency. Nephrol Dial Transprant 16 : 1870-1878, 2001.
 
17) Kinugasa E, Kishikawa S, The PB-94 Study Group : Effect of PB94 (sevelamer hydrochloride), aphosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients-A ramdomized, open label, dose titration study of PB-94 versus Caltan tablet 500 (calcium carbonate). J Am Soc Nephrol 12 (Suppl.) : A3943, 2001.
 
18) Joy MS, Finn WF, Lanthanum Study Group : Result of a randomized, phase, dose titration, paralel group study of lanthanum carbonate for reduction and maintenance of serum phosphate in chronic hemodialysis. J Am Soc Nephrol 12 (Suppl.) : A1996, 2001.
 
19) Joy MS, Finn WF, Lanthanum Study Group : Safety profile of lanthanum carbonate in hemodialysis padents ; Results from a phase III U. S. study. J Am Soc Nephrol 12 (Suppl.) : A1997, 2001.
 
20) Levine BS, Song M : Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 7 : 488-496, 1996.
PubMed
21) Martin KJ, Gonzalez EA, Gellens M, et al. : 19-Nor-1α-25-dihydroxyvitamin D2 (Paricarcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9 : 1427-1432, 1998.
 
22) Tan AU, Levine BS, Mazess RB, et al. : Effective suppression of parathyroid hormone by 1α-hydroxyvitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney hlt 51 : 317-323, 1997.
 
23) Cozzolino M, Lu Y, Finch JL, et al. : p21 and TGF-α mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 60 : 2109-2117, 2001.
 
24) Wada M, Fuyuya Y, Sakiyama J, et al. : The calcimimetic dompound NPS R-568 suppress parathyroid cell proliferation in rats with renal insufficiency. J Clin Invest 100 : 2977-2983, 1997.
 
25) Wada M, Ishi H, Furuya Y, et al. : NPS R-56 8 halts or reverses ostitis fibrosa in uremic rats. Kidney Int 53 : 448-453, 1998.
 
26) Goodman WG, Hladik GA, Tumer SA, et al. : The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13 : 1017-1024, 2002.
 
27) Solbiati L, Giangrande A, Pra RD, et al. : Percutaneous ethanol injection of parathyroid tumors under US Guidance ; Treatment for secondary hyperparathyroidism. Radiology 155 : 607-610, 1985.
 
28) Giangrande A, Castigloni A, Solbiati L, et al. : Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant 7 : 412-421, 1992.
PubMed
29) Sherrard DJ, Ott SM, Maloney N, et al. : Uremic osteodystrophy ; classification cause and treatment. In : Clinical Disorders of Bone and Mineral Metabolism (Frame B, Potts JT Jr, eds), Excepta Medica Amsterdam, 1983, pp254-259.
 
30) Sherrard DJ, Hercz G, Pei Y, et al. : The spectrum of bone disease in endstage renal failure-an evolving disorder. Kidney int 43 : 436-442, 1993.
PubMed
31) Gupta A, Kallenbach LR, Zasuwa G, et al. : Race is a major factor of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 11 : 330-334, 2000.
 
32) Goodman WG, Ramirez JA, Belin TR, et al. : Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46 : 1160-1166, 1994.
PubMed
33) Monier-Faugere MC, Geng Z, Mawad H, et al. : Improved assessment of bone turnover by the PTH- (1-84) /large C-PTH fragments ratio in ESRD patients Kidney Int 60 : 1460-1468, 2001.
 
34) Picton ML, Moore PR, Mawer B, et al. : Downregulation of human osteoblast PTH/PT-HrP receptor mRNA in endstage renal failure. Kidney Int 58 : 1440-1449, 2000.
 
35) Kazama J, Fukagawa M, Shigematsu T, et al. : Increased circulating osteoprotegerin modifies bone metabolism in uremic patients J Am Soc Nephrol 11 : 565A, 2000.
 
36) Gonzalez EA, Martin KJ : Coordinate regdation of PTH/PTH-rP receptors by PTH and calcitriol in UMR 106-01 osteoblast-Uke cell. Kidney Int 50 : 63-70, 1996.
 
37) Hruske K : New concepts in renal osteodystrophy. Nephrol Dial Transprant 13 : 2755-2760, 1998.
 
38) Jehle PM, Ostertag A, Schultenk, et al. : Inslin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Kidney Int 57 : 423-426, 2000.
 
39) Neer RM, Arnaud CD, Zanchetta JR, et al. : Elifect of parathyroid hotmone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 344 : 1434-1441, 2001.
PubMed
40) Gowen M, Stroup GB, Dodds RA, et al. : Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 105 : 1595-1604, 2000.
PubMed
P.39 掲載の参考文献
1) Yamaguchi A, Komori T, Suda T : Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev 21 : 393-411, 2000.
PubMed
2) Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ : Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20 : 345-357, 1999.
PubMed
3) Manolagas SC, Jnka RL : Bone marrow, cytoknes and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332 : 305-311, 1995.
 
4) Hoshi K, Kemmotsu S, Takeuchi Y, Amizuka N, Ozawa H : The primary calcification in bones fbllows removal of decorin and fusion of collagen fibrils. J Bone Miner Res 14 : 273-280, 1999.
PubMed
5) Brown EM, MacLeod RJ : Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81 : 239-297, 2001.
PubMed
6) Romas E, Gillespie MT, Martin TJ : Involvement of receptor activator of NFkapPaB Hgand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30 : 340-346, 2002.
 
7) Kazama JJ, Maruyama H, Gejyo F : Osteoclastogenesis and osteoclast activation in dialysisrelated amyloid osteopathy. Am J Kidney Dis 38 (4 Suppl. 1) : S156-160, 2001.
 
8) Slatopolsky E, Brown A, Dusso A : Pathogenesis of secondary hyperparathyroidism. Kidney Int 73 (Suppl.) : S14-19, 1999.
PubMed
9) Slatopolsky E, Brown A, Dusso A : Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37 (1 Suppl 2) : S54-57, 2001.
 
10) Massry SG, Stein R, Garty J, Arieff AI, Coburn JW, Norman AW, Friedler RM : Skeletal resistance to the calcemic action of parathyroid homone in uremia role of 1,25 (OH) 2D3. Kidney Int 9 : 467-474, 1976.
 
11) Fukagawa M, Kazama JJ, Shigematsu T : Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. Am J Kidney Dis 38 (4 Suppl. 1) : S152-155, 2001.
 
12) Quarles LD, Lobaugh B, Murphy G : Intact parathyroid hormone overestimates the presence and severity of parathyroidmediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75 : 145-150, 1992.
PubMed
13) Galceran T, Martin KJ, Morrissey JJ, Slatopolsky E : Role of 1, 25-dihydroxyvitamin Don the skeletal resistance to parathyroid hormone. Kidney Int 32 : 801-807, 1987.
 
14) Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, Gokal R, Hoyland JA : Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 58 : 1440-1449, 2000.
PubMed
15) Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A : A novel mechanism fbr skeletal resistance in uremia. Kidney Int 58 : 753-761, 2000,
 
16) Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K Fukagawa M : lhcreased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 39 : 525-532, 2002.
PubMed
17) Kazama JJ, Kutsuwada K, Ataka K, Maruyama H, Gejyo F : Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. Nephron 91 : 13-20, 2002.
PubMed
18) Tominaga Y : Mechanism of parathyroid tumourigenesis in uraemia. Nephrol Dial Transplant 14 (Suppl. 1) : 63-65, 1999.
 
19) Fukagawa M : Cell biology of parathyroid hyperplasia in uremia. Am J Med Sci 317 : 377-382, 1999.
PubMed
20) Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y : Decreased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92 : 1436-1443, 1993.
PubMed
21) Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB : Depressed expression of calcium receptor in parathyroid gland tissue of patients with hypelparathyroidism Kidney Int 51 : 328. 336, 1997.
 
22) Rodriguez M, Canalejo A, Garfia B, Aguilera E, Almaden Y : Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int 61 (Suppl. 80) : 155-160, 2002.
 
23) Salusky IB, Goodman WG : Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 17 : 336-339, 2002.
PubMed
24) Malluche HH, Monier-Faugere MC : The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 4 : 1631-1642, 1994.
PubMed
P.47 掲載の参考文献
1) 伊藤美紀子, 瀬川博子, 桑波田雅士, 他 : 無機リン酸トランスポーターファミリー. Annual Review腎臓, 22-26, 2002.
 
2) Murer H, Hernando N, Foster I, et al. : Physiol Rev 80 : 1373-1409, 2000.
 
3) Segawa H, Kaneko I, Takahashi A, et al. : Growth-related type II Na/Pi cotransporter. J Biol Chem. in press 2002,
 
4) Miyamoto K, Ito M, Segawa H, et al. : Secondary hyperparathyroidism and phosphate sensing in parathyroid glands. J Med Invest 47 : 118-122, 2000.
PubMed
5) Hilfiker H, Hattenhauser O, Traebert M, et al. : Characterization of a new murine type II sodium-phosphate cotransporter expressed in mammalian smaU intestine. Proc Natl Acad Sci USA 95 : 14564-14569, 1998.
 
6) Katai K, Miyamoto K Kishida S, et al : Regulation of intestinal Na+-dependfent phosphate cotransporter by low-phosphate diet and 1, 25-dihydroxyvitamin D3. Biochem J 343 : 705-712, 1999.
PubMed
7) Tsukita Sh, Furuse M, Itoh M : Multifunctional strands in tight junctions. Nature Rev Mol Cel Biol 2 : 285293, 2001.
 
8) HYP Consonium : A gene (PEX) with homologies to endopeptidases is mutated in patients with X-liked hypophosphatemic rickets Nat Genet 11 : 130-136, 1995.
PubMed
9) The ADHR Consortium : Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF-23. Nat Genet 26 : 345-348, 2000.
PubMed
10) Yamamoto T, Mitamoto K, Ozono K, et al. : Hypophosphatemic rickets accompanying McCune-Albright syndrome : evidence that a humoral factor causes hypophosphatemia. J Bone Mineral Metab 19 : 287-295, 2001.
 
11) 椎崎和弘, 秋澤忠男 : 高リン血症に対する新しい薬剤. 腎と骨代謝 15 : 75-80, 2002.
 
12) Nagano N, Miyata S, Obana S, et al. : Sevelamer hydrochloride (Renagel), a non-calcemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufiiciency. Nephrol Dial Transplant 16 : 1870-1878, 2001.
 
13) Katai K, Tanaka H, Tatsumi S, et al. : Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 14 : 1195-1201, 1999.
PubMed
P.48 掲載の参考文献
1) Fukagawa M : Phosphate as another major regulator of parathyroid function. Intern Med 39 : 440-1, 2000.
PubMed
2) Miyamoto KI, Itho M : Transcriptional regulation of the NPT2 gene by dietary phosphate. Kidney Int 60 : 412-5, 2001.
PubMed
3) Yi H, Fukagawa M, Yamato H, Kumagai M, Watanabe T, Kurokawa K : Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats : possible direct rgle of phosphorus. Nephron 70 : 242-8, 1995.
 
4) Frazer DM, Wilkins SJ, Becker EM, Vulpe CD, McKie AT, Trinder D, Anderson GI : Hepcidin expression inversely correlates with the expression of duodenal ion transporter and iron absorption in rats. Gastroenterology 123 : 835-844, 2002.
 
5) Almaden Y, Hernandez A, Torregrosa V, CanalejoA, Sabate L, Fernandez Cruz L, Campistol JM, Torres A, Rodriguez M : High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 9 : 1845-52, 1998.
 
6) Ritter CS, Finch JL, Slatopolsky EA, Brown AJ : Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int 60 : 1737-44, 2001.
PubMed
7) Kurokawa K, Fukagawa M : Uremic bone diseases : Advances over the last 30 years. J Nephrol 12 (Supple 2) : S63-67, 1999.
 
P.58 掲載の参考文献
1) Coburn JW, Sherrard DJ, Ott SM, et al. : Bone disease in uremia. In : Biochemical and Clinical Endocrinology of Calcium Metabolism (Norman AW ed) : 827-831, 1982.
 
2) Sherrard DJ, Hercz G, Pei Y, et al. : The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int 43 : 436-442, 1993.
PubMed
3) Krieger NS : Bone formation, resorption, and turnover. In : Renal osteodystrophy (Bushinsky DA ed), Lippincott-Raven Publishers, Philadelphia, 17-47, 1998.
 
4) 恵以盛, 谷澤龍彦, 荒川正昭 : 骨病変の組織診断腎と骨代謝ハンドブック (黒川清監修), 日本メディカルセンター, 東京, 178-186, 1997.
 
5) 高橋栄明 : 骨の組織学的パラメーター. 高橋栄明編 : 骨形態計測ハンドブック. 西村書店, 新潟, 17-24, 1992.
 
6) 栗原怜, 大和田一博 : アルミニウム, 鉄の骨組織に与える影響. 腎と骨代謝, 10 : 49-56, 1997.
 
7) 栗原怜, 大和田一博, 小野田教高, 他 : ビタミンD3の欠乏により線維性骨炎がマスクされたと考えられる高度の二次性副甲状腺機能亢進症の1例. CLINICAL CALCIUM 9 : 1582-1586, 1999.
 
8) 高橋栄明, 伊藤明美, 山本智明, 他 : 腎性骨異栄養症における線維組織を伴う無形成骨症の検討. 日骨形態誌 11 : S37, 2001.
 
9) 小野田教高, 栗原怜, 桜井祐成, 他 : 副甲状腺PAIT (経皮的酢酸注入療法) にて良好にコントロールされた腎性副甲状腺機能亢進症の1例. 腎と透析 50 (別冊) : 96-98, 2001.
 
10) Wang M Hercz G, Sherrard D, et al. : Relationship between intact l-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 26 : 836-844, 1995.
PubMed
11) Quares D, Lobaugh B, Murphy G, et al : Intact parathyroid hormone overestimate the presence and severity of parathyroid mediated osseous abnomalities in uremia J Clin Endocrinol Metab 75 : 145-150, 1992.
 
12) 大和田一博, 栗原怜, 竹内正至, 他 : 維持透析患者における骨型アルカリフォスファターゼ (BALP) と骨組織との関連. 日腎会誌 40 : 166, 1998.
 
13) Kurihara S, Takeuchi M, Yoneshima H, et al. : Bone mineral density of radial bone reflects the degree of ostitis fibrosa in hemodialysis patients Nephrology 3 (Supple 1) : s175, 1997.
 
14) Tominaga Y, Tanaka Y, Sato K, et al. : Histology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Sem Surg Oncol 13 : 78-76, 1997.
 
15) Onoda N, Kurihara S, Yoneshima H, et al. : Usefulness of ultrasonographic power-doppler imging of parathyroid hyperplasia in renal hyperParathyroidism JASN 9 : 569A, 1998.
 
16) 大和田一博, 栗原怜 : パルス療法によるPTH抑制の臨床効果. 腎と骨代謝 8 : 183-190, 1995.
 
17) 栗原怜, 秋葉隆, 谷澤龍彦, 他 : 維持透析患者における二次性副甲状腺機能亢進症に対する22-oxacalcitriol (OCT) 投与時の骨組織学的検討. 腎と透析 47 : 559-572, 1999.
 
P.70 掲載の参考文献
1) Cauley JA, Thompson DE, Ensrud KC, et al. : Risk of mortality following clinical fractures. Osteoporos Int 11 : 556-561, 2000.
PubMed
2) Lindberg JS, Moe SM : Osteoporosis in end-stage renal disease. Semin Nephrol 19 : 115-122, 1999.
 
3) 森井浩世 : 骨粗鬆症の概念と定義の変遷. 日本臨牀 60 (増刊号3) : 9-12, 2002.
Medical*Online
4) 折茂肇, 林泰史, 福永仁夫, 他 : 原発性骨粗鬆症の診断基準 (2000年度改訂版). 日本骨代謝学会雑誌 18 : 76-82, 2001.
Medical*Online
5) Balon BP, Bren A : Bone histomorphometry is still the golden standaer for diagnosing renal osteodystrophy. Clin Nephrol 54 : 463-469, 2000.
 
6) 森田有津子, 三木隆己 : 腎性骨異栄養症 (ROD) の測定. In : 森田陸司監修, 骨粗鬆症と骨塩定量. メディカルレビュー社, 東京, p113-119, 1994.
 
7) Gerakis A, Hadjidakis D, Kpkkinakis E, et al. : orrelation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 13 : 437-443, 2000.
 
8) Miki T, Morita A, Nakatsuka K, et al. : Changes in bone mineral density at various sites in patients on hemodialysis due to chronic glomerulonephritis Osteoporos int 7 (Suppl 3) : S193-Sl96, 1997.
 
9) 奥野仙二, 金昌雄, 出雲谷剛, 他 : 高齢の男性透析患者の骨塩量の変化についての検討. 透析会誌 31 (Suppl 1) : 717, 1998.
 
10) Taal MW, Masud T, Green D, et al. : Risk factors for reduced bone density in haemodialysis patients Nephrol Dial Transplant 14 : 1922-1928, 1999.
PubMed
11) Fontaine MA, Albert A, DubOis B, et al. : Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 54 : 218-226, 2000.
PubMed
12) Stein MS, Packham DK, Ebeling PR, et al. : Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 28 : 515-522, 1996.
PubMed
13) Stehman-Breen CO, Sherrard D, Walker A, et al. : Racial differences in bone mineral density and bone loss among end-stage renal disease patients. Am J Kidney Dis 33 : 941-946, 1999.
PubMed
14) Fletcher S, Jones RG, Rayner HC, et al. : Assessment of renal osteodystrophy in dialysis patients : use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 75 : 412-419, 1997.
PubMed
15) Stein MS, Packham DK, Wark JD, et al. : Response to parathyroidectomy at the axial and appendicular skeleton in renal patients. Clin Nephrol 52 : 172-178, 1999.
PubMed
16) Arici M, Erturk H, Altun B, et al. : Bone mineral density in haemodialysis patients : a comparative study of dual, energy X-ray absorptiometry and quantitative ultrasound. Nephrol Dial Transplant 15 : 1847-1851, 2000.
PubMed
17) 奥野仙二, 金昌雄, 長末京子, 他 : 男性透析患者における骨塩量の変化と骨代謝マーカーの関連についての検討. 透析会誌 34 (Suppl 1) : 730, 2001.
 
18) Stehman-Breen CO, Sherrard DJ, Alem AM, et al. : Risk factors fbr hip fracture among patients with end-stage renal disease. Kidney Int 58 : 2200-2205, 2000.
 
19) Yamaguchi T, Kanno E, Tsubota J, et al. : Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 19 : 549-555, 1996.
 
P.77 掲載の参考文献
1) Hayashi S, Noshiro M, Okuda K : Isolation of a cytochrome P-450 that catalyzes the 25-hydroxylation of vitamin D3 from rat liver microsomes. J Biochem 99 : 1753-63, 1986.
PubMed
2) Shinki T, Shimada H, Watoson S, et al. : Cloning and expression of rat 25-hydroxyvitamin D3-1α-hydroxylase cDNA. Proc Natl Acad Sci USA 94 : 12920-12925, 1997.
 
3) Yumita S, Suzuki M, Akiba T, Akizawa T, Seino Y, Kurokawa K : Level of serum 125 (OH) 2D in patients with pre-dialysis chronic renal failure. Tohoku J Exp Med 180 : 4556, 1996.
 
4) Dusso A, Lopez-Hilker S, Rapp N, et al : Extrarenal production of calcitriol in chronic renal failure. Kidney Int 34 : 368-75, 1988.
PubMed
5) Inaba M, Okuno S, NishiZawa Y, et al. : Effect of substituting fluorine for hydrogen at C-26 and C-27 on the side chain of 125-dihydroxy Vitamin D, . Biochem Pharmacol 45 : 2331-2336, 1993.
 
6) Brown AJ, Finch J, Grieff M, et al. : The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84 (3) : 728-732, 1989.
 
7) Fukushima M, Suzuki Y, Tohira Y, Matsunaga I, Ochi K, Nagano H, Nishii Y, Suda T : Metabolism of 1α-hydroxyvitamin D3 to 1α, 25-dihydroxyvitamin D3 in perfused rat liver. Biochem Biophys Res Commun 66 : 6328, 1975.
 
8) Kumaki K, Fukushima M, Shimizu T, Ogawa M, Hinohara Y, Tohira Y, Nakano H, Takanashi S, Nishii Y, Abe E, Suda T : Metabolism of 25-hydroxycholecalciferol and 1α-hydroxycholecalciferol in experimental rat with chronic renal failure. Vitamins 52 : 399, 197&
 
9) 弓田滋 : 血液透析中の慢性腎不全患者における活性型ビタミンD製剤の体内動態と血中1, 25 (OH) 2Dの評価. 医学と薬学 41 (4) : 603-607, 1999.
Medical*Online
10) Yumita S, Sekino H, Yamauchi S, et al. : Oral 1, 25-dihydroxyvitamin D3 loading test in rlormal subjects and patients with chronic renal failure under haemodialysis. Nephrology 2 : 339-343, 1996.
 
11) Hsu CH, Patel SR, Young EW : Mechanism of decreased calcitriol degradation in renal failure. Am J physiol 262 : 1928, 1992.
 
12) Beckman MJ, Tadikonda P, Werner E, et al. : Human 25hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 35 : 8465-8472, 1996.
PubMed
13) Shigematsu T, Kawaguchi Y, Unemura S, et al : Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1, 25-dihydroxycholecalciferol. Intern Med 32 : 695-701, 1993.
PubMed
14) Kobayashi T, Okano T, et al : Metabolism and transporting system of 22-oxacalcitriol. Contrib Nephrol 91 : 129-133, 1991.
PubMed
15) Okano T, Tsugawa N, et al. : Protein-binding propertyes of 22- oxa-1α,25-dihydroxyvitamin D3, a synthetic analogue of 1α,25-dihydroxyvitarmin D3. J Nutr Sci Vitaminol 35 : 529-533, 1989.
 
16) Watanabe Y, Kubota T, Suzumura E, Suzuki T, Yonezawa M, Ishigami T, Ichikawa M, Seino Y : 1, 25-dihydroxyvitamin D radioreceptor assay using bovine mammary gland receptor and non-high performance liquid chromatographic purification. Clin Chim Acta 225 : 187-194, 1994.
PubMed
17) 田中弘之, 清野佳紀, Wei S, Liu L, 弓田滋 : Radioimmunoassayを用いた血中1, 25-Dihydroxy-vitamin D測定キットの検討-各種ビタミンD代謝物との交差反応を中心に. ビタミン 72 (11) : 607-611, 1998.
 
P.80 掲載の参考文献
1) Ashman N, Malluche HH, Cunniggham J : Hypercalcemia and human nature. Clinical Nephrology 55 : 327-330, 2001.
 
2) Down PF, Polak A, Regan RJ : A familym with massive acute vitamin D intoxication. Postgraduate Medical J 55 : 897-902, 1979.
 
3) Pettifo JM, Bikle DD, Cavaleros M, Zachen D, Kamdar MC, et al. : Serum levels of free lα25dihydroxy-vitamin D in vitamin D toxicity. Ann Int Med 122 : 511-513, 1995.
 
4) Blank S, Acanlon KS, Sink TH, Lett S, Falk H An outbreak of hypervitaminosis D associated with the overfortification of milk from home-delivery dairy. Am J Public Health 85 : 656-659, 1995.
 
5) Vieth R, Pinto TR, Reen BS, Wong MM : Vitamin D poisoning by table sugar. Lancet 359 : 672, 2002.
PubMed
6) Koutkia P, Chen TC, Holick MF : Vitamin D intoxication associated with an over-the counter supplement. N Engl J Med 345 : 66-67, 2001.
PubMed
7) Vieth R, Chan CR, Macfarlane GD : Efficacy and safety of vitamin D : i intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 73 : 288-294, 2001.
 
8) Inui N, Murayama A, Sasaki S, Suda T, Chida K, et al. : Correlation between 25 hydroxylase D31hydroxylase gene expression in alveolar macrphages and the activity of sarcoidosis. Am J Med 110 : 687-693, 2001.
 
9) Class AR, Cerletty JM, Elliot W, Lemann J Jr, Gray RW, et al. : Ketoconazole reduces elevated serum levels of 1α25dihydroxy-vitamin D in hypercalcemic sarcoidosis. J Endocrinol Invest 13 : 407-417, 1990.
 
P.90 掲載の参考文献
1) Takeyama K, Kitanaka S, Sato T, et al. : 25-hydroxyVitamin D3 1α-hydroxylase and vitamin D synthesis. Science 277 (19 September) : 1827-1830, 1997.
 
2) Coburn JW, Elangovan L : Prevention of metabolic bone disease in the pre-end-stage renal disease setting. J Am Soc Nephrol (12 Suppl) : S71-77, 1998.
 
3) Slatopolsky E, Brown A, Dusso A : Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37 (1 Suppl 2) : S54-57, 2001.
 
4) Christiansen C, Rodbro P, Christensen MS, et al. : Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 8092 (II) ; September 30 : 700-703, 197&
 
5) 加藤尚彦, 笠井健司, 川口良人, 他 : 慢性腎不全保存期の1, 25 (OH) 2D3療法. 日本腎臓学会誌 37 (10) : 543-548, 1995.
 
6) 重松隆, 山本裕康 : 維持透析患者における目標PTH値はrelative Hypoparathyroidismの低めのレベル (intact-PTHで100～150pg/ml) を薦めたい. 腎と骨代謝 14 (1) : 67-73, 2001.
 
7) Akiba T, Marumo F, Owada A, et al. : Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 32 : 238-246, 1998.
PubMed
8) Mizumoto D, Watanabe Y, Fukuzawa Y, et al. : Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3. Nephrol Dial Transplant 9 : 1751-1758, 1994.
PubMed
9) Kikunami K, Nishizawa Y, Tabata T, et al. : Changes in parathyroid hormone in diabetic patients on long-term hemodialysis. Nephron 54 : 318-321, 1990.
PubMed
10) Yokoyama K, Shigematsu T, Tsukada T, et al. : Apa I polymorphism in the vitamin D receptor gene may affect the parathyroid response in Japanese with end-stage renal disease. Kidney Int 53 : 454-458, 1998.
PubMed
11) Yokoyama K, Shigematsu T, Tsukada T, et al. : Calcium-sensing receptor gene polymorphism affects the parathyroid response to moderate hypercalcernic suppression in patients with endstage renal disease. Clin Nephrol 57 : 131-135, 2002.
PubMed
12) Nagy A, Chudek J, Kovacs G : Accumulation of allelic changes at chromosomes 7p, 18q and 2 in parathyroid lesions of uremic patients. Lab Invest 81 : 527-533, 2001.
PubMed
13) Dusso AS, Pavlopoulos T, Naumovich L, et al. : p21 (WAF1) and transforming growth factoralpha mediate dietary phosphate regulation of parathyroid cell growtlL Kidney Int 59 : 855-865, 2001.
PubMed
14) Argiles A, Mion CM : Low-calcium dialysate worsens secondary hyperParathyroidism. J Am Soc Nephrol 7 : 635636, 1996.
 
15) Katoh N, Nakayama M, Shigematsu T, et al. : Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis 35 : 465-468, 2000.
PubMed
16) Fukagawa M, Kitaoka M, Kurokawa K : Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients : a theoretical approach. Nephrol Dial Transplant 11 (Suppl 3) : 125-129, 1996.
 
17) Yano S, Sugimoto T, Tsukamoto T, et al. : Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cels in secondary hyperparathyroidism. Kidney Int 58 : 1980-1986, 2000.
 
18) Valimaki S, Farnebo F, Forsberg L, et al. : Heterogeneous expression of receptor mRNAs in parathyroid glands of secondary hyperparathyroidism. Kidney Int 60 : 1666-1675, 2001.
PubMed
19) Shigematsu T, Kawaguchi Y, Unemura S, et al. : Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1, 25-dihydroxycholecalciferoL Intern Med 32 : 695-701, 1993.
PubMed
20) Madsen S, Olgaard K, Ladefbged J : Suppressive effect of 1,25-dihydroxyvitamin D3 on circulating parathyroid hormone in acute renal failure. J Clin Endocrinol Metab 53 : 823-827, 1981.
PubMed
21) Slatopolsky E, Weerts C, Thielan J, et al. : Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-diydrooxycholecalciferol hl uremic patients J Clin Invest 74 : 2136-2143, 1984.
 
22) Akizawa T, Suzuki M, Akiba T, et al. : Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 38 (4 Suppl 1) : S147-151, 2001.
 
23) Pemalete N, Mori T, Nishii Y, et al. : The activity of 22-oxacalcitriol in osteoblast-like (ROS 17/28) cells Endocrinology 129 : 778-784, 1991.
 
24) Finch JL, Brown AJ, Kubodera N, et al. : Differential effects of 1, 25- (OH) 2D3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int 43 : 561 ; 566, 1993.
 
25) Brown AJ, Finch J, Grieff M, et al. : The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 133 : 1158-1164, 1993.
PubMed
26) Brown AJ, Ritter CR, Finch JL, et al. : The noncalcemic analogue of vitamin D, 22-oxacalcitrioL suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84 : 728-732, 1989.
PubMed
27) Takeyama K, Masuhiro Y, Fuse H, et al. : Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol 19 : 1049-1055, 1999.
 
28) 重松隆, 山本裕康 : Calcimimeticsの臨床応用-二次性副甲状腺機能亢進症-. CLINICAL CALCIUM 8 : 1482-1488, 199&
 
29) Velentzas C, Meindok H, Oreopoulos DG, et al. : Visceral calcification and the CaXP product. Adv Exp Med Biol 103 : 195-201, 197&
 
30) 村山明子, 重松隆 : 高・低リン血症. 腎と骨代謝ハンドブック (黒川清監修, 鈴木正司, 秋澤忠男, 松本俊夫, 塚本雄介編集), p129-142, 日本メディカルセンター, 東京, 1997.
 
P.93 掲載の参考文献
1) John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, et al. : A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments implication for PTH measurements in renal failure. J Clin Endocrinol&Metab 84 : 4287-4290, 1999.
 
2) Gao P, Scheibel S, D'anour P, John MR, Rao SD, et al. Development of a novel immunoradiometric assay exclusively for biological active whole parathyroid hormone 1-84 ; Implications for improvement of accurate assessment of parathyroid function. J Bone and Miner Res 16 : 605-614, 2001.
 
3) Nakanishi S, Kazama JJ, Shigematu T, Iwasaki Y, Cantor TL, et al. : Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am J Kidney Dis 38 : s172-s174, 2001.
 
4) Slatopolosky E, Finch J, Clay P, Martin D, Sicard G, et al. : A novel mechanism for skeletal resistance in uremia. Kidney Int 58 : 753-761, 2000.
 
5) Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, et al. : PTH1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 40 : 348-354, 2002.
 
P.101 掲載の参考文献
1) Albright F, Drake TG, Sulkowitch HW : Renal osteitis fibrosa cystica : Report of case with discussion of metabolic aspects. Johns Hopkins Med J 60 : 377-385, 1937.
 
2) Fraser DR Kodicek E : Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 228 : 764-766, 1970.
PubMed
3) Chertow GM, Burke SK, Lazarus JM, et al. : A normocalcemic hosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29 : 66-71, 1997.
 
4) Brown EM, Gamba G, Riccardi D, et al. : Cloning and characterization of an extracellular Ca2+ -sensing receptor from bovine parathyroid. Nature 366 : 575 580, 1993.
 
5) Slatopolsky E, Caglar S, Gradowska L, et al. : On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using proportional reduction of dietary phosphorus intake Kidney Int 2 : 147-151, 1972.
PubMed
6) Hodsman AB, Sherrard DJ, Wong EGC, et al. : Vitamin D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism.Ann Intern Med 94 : 629-637, 1981.
 
7) Sherrard DJ, Hercz G, Pei Y, et al. : The spectrum of bone disease in end-stage renal faHure-an evolving disorder. Kidney Int 43 : 436-442, 1993.
PubMed
8) 日本透析療法学会統計調査委員会 : わが国の慢性透析療法の現況 (2000年12月31日現在)
 
9) Consensus Development Conference. Consensus development conference : Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94 : 646, 1993.
PubMed
10) Kanis JA, Melton LJ III, Christiansen C, et al. : The diagnosis of osteoporosis. J Bone Miner Res 9 : 1137, 1994.
 
11) 折茂肇, 他 : 原発性骨粗鬆症の診断基準. 日本骨代謝会誌 18 : 76-82, 2001.
 
12) 折茂肇, 他 : 骨粗鬆症の治療 (薬物療法) に関するガイドライン. Osteoporos Jpn 6 : 205-253, 1998.
 

書評

最近チェックした商品履歴

Loading...